InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

- Current share price for MSB : $2.380

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$3,091 Mesoblast to Host R&D Day on April 8, 2026 18 Mar 2026 9:54AM $2.020 $2.380 risen by 17.82%
$3,091 Replacement Appendix 3Y for Gregory George 12 Mar 2026 5:05PM $2.140 $2.380 risen by 11.21%
$3,091 Appointment of Clinical Development and Medical Affairs Head 12 Mar 2026 9:58AM $2.190 $2.380 risen by 8.68%
$3,091 Becoming a substantial holder 10 Mar 2026 3:28PM $2.170 $2.380 risen by 9.68%
$3,091 Appendix 3Y for Gregory George 10 Mar 2026 9:39AM $2.110 $2.380 risen by 12.80%
$3,091 Change in substantial holding 9 Mar 2026 11:33AM $2.120 $2.380 risen by 12.26%
$3,091 Ryoncil Profits Underpinning Substantial Growth Pipeline 27 Feb 2026 9:02AM $2.420 $2.380 fallen by 1.65%
$3,091 Corporate Presentation and Half Year Financial Results 27 Feb 2026 8:49AM $2.420 $2.380 fallen by 1.65%
$3,091 Half Year Report and Accounts (including Appendix 4D) 27 Feb 2026 8:42AM $2.420 $2.380 fallen by 1.65%
$3,091 Mesoblast 2026 Half Year Financial Results Webcast 20 Feb 2026 4:53PM $2.410 $2.380 fallen by 1.24%
$3,091 High Survival Rates with Ryoncil in SR-aGvHD EIND Program 12 Feb 2026 10:02AM $2.550 $2.380 fallen by 6.67%
$3,091 Becoming a substantial holder 9 Feb 2026 8:11AM $2.230 $2.380 risen by 6.73%
$3,091 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jan 2026 10:05AM $2.680 $2.380 fallen by 11.19%
$3,091 Real World Experience with Ryoncil Shows 84% Early Survival 27 Jan 2026 10:20AM $2.650 $2.380 fallen by 10.19%
$3,091 Ceasing to be a substantial holder 27 Jan 2026 8:25AM $2.680 $2.380 fallen by 11.19%
$3,091 Becoming a substantial holder 27 Jan 2026 8:10AM $2.680 $2.380 fallen by 11.19%
$3,091 FDA Confirms Path to Approval for CLBP 19 Jan 2026 10:04AM $2.640 $2.380 fallen by 9.85%
$3,091 Notification of cessation of securities - MSB 15 Jan 2026 5:53PM $2.700 $2.380 fallen by 11.85%
$3,091 Notification regarding unquoted securities - MSB 15 Jan 2026 5:49PM $2.700 $2.380 fallen by 11.85%
$3,091 Notification regarding unquoted securities - MSB 13 Jan 2026 7:15PM $2.730 $2.380 fallen by 12.82%
$3,091 Application for quotation of securities - MSB 13 Jan 2026 7:06PM $2.730 $2.380 fallen by 12.82%
$3,091 Appendix 3Y for Eric Rose 13 Jan 2026 6:58PM $2.730 $2.380 fallen by 12.82%
$3,091 Appendix 3Y for Lyn Cobley 12 Jan 2026 9:52AM $3.070 $2.380 fallen by 22.48%
$3,091 Ryoncil Sales for the Quarter Increase 60% to US$35.1M 9 Jan 2026 9:57AM $2.950 $2.380 fallen by 19.32%
$3,091 Appendix 3Y for Gregory George 6 Jan 2026 6:31PM $2.740 $2.380 fallen by 13.14%

51 - 75 of 1186 results

Page 3 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.